Question of the Day – Monday July 15, 2019
Question - When exposure to burning poisonous plants is unavoidable, employers should provide workers with what form of respiratory protection?
Question of the Day – Friday July 12, 2019
Question - What is the so-called “HAZWOPER” program?
Question of the Day – Thursday July 11, 2019
Question - What are the so-called GenX chemicals?
Question of the Day – Wednesday July 10, 2019
Question - PD-1/PD-L1 inhibitors have recently been approved for the treatment of a number of malignancies. The use of PD-1 axis inhibition is drastically changing the use of immunotherapy in cancer. What are the novel immune related adverse effects associated with the use of these agents?
Question of the Day – Tuesday July 9, 2019
Question - The article cited below reports the drug “Dexmedetomidate induces sedation while preserving a degree of arousability among patients in the intensive care unit (ICU), and its use has resulted in a shorter time to extubation, an increased number of days free from coma or delirium, a reduced incidence of agitated delirium, prevention of delirium, and lower mortality than other agents administered in certain populations.” What adverse effects are reported in association with the administration of dexmedetomidate?
Question of the Day – Monday July 8, 2019
Question - What factors account for the summer seasonal peak of Cryptosporidium related infections?
Question of the Day – Wednesday July 3, 2019
Question - What are the most common adverse effects of etomidate?
Question of the Day – Tuesday July 2, 2019
Question - What is the mechanistic basis for the CNS effects associated with loperamide overdose?
Question of the Day – Monday July 1, 2019
Question - What are the medications that have been reported to increase the risk for classic heatstroke as opposed to exertional heat stroke?